Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte Inc LSE:MXCT London Ordinary Share COM STK USD0.01 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.00 0.22% 900.00 890.00 910.00 903.00 888.00 900.00 58,934 08:00:20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 16.3 -9.7 -17.3 - 669

Maxcyte Share Discussion Threads

Showing 676 to 698 of 750 messages
Chat Pages: 30  29  28  27  26  25  24  23  22  21  20  19  Older
DateSubjectAuthorDiscuss
05/5/2021
10:01
Never a good sign when the focus centres on selling shares to the Yanks instead of selling stuff to customers.
trident5
05/5/2021
09:36
...Good article. Importantly, this isn't just another UK stock trying to artificially raise their share price by getting a Nasdaq listing. This IS a US company with US directors, premises and mojority US customers. The fact that they couldn't talk about the US listing with the recent results shows that things are moving fast in the background and they will announce listing initiation soon. Nasdaq listing will have a huge impact.
someuwin
05/5/2021
06:19
Telegraph Questor today:Questor: a 'very special company' about to list where investors will be besotted with itQuestor share tip: MaxCyte offers huge potential but it may take a new listing on Nasdaq to get the share price higher stillWe can have no complaint about the performance of shares in MaxCyte, whose hi-tech machines help drugs firms make gene editing treatments: tipped at 370p in October last year, when we said they might be worth 500p, they closed last night at 886p and were as high as £10.40 in February.Normally we'd consider selling when a target price has been breached so comprehensively but MaxCyte finds itself in an anomalous position that it is about to rectify, a process that could do wonders for the share price.The company is based in America, has a roster of clients that are largely American and is the type of business that generates great enthusiasm among American investors – yet its shares trade on London's Aim market. It would make far more sense to have a listing on the stock market favoured by its natural investors – the Nasdaq in New York – and the company is in the process of getting just such a listing.In the words of Richard Penny of Crux Asset Management, which owns a stake in MaxCyte, "investors in the US are besotted with gene editing – they are hugely buoyant about what they see as the third age of drug discovery" built on the decoding of the human genome 20 years ago.Besotted investors are in much shorter supply here. Britain may have a huge fund management industry but when it comes to the healthcare sector it lacks the critical mass in terms of specialist analysts, funds and brokers found in America.In fact, you could say we are positively hostile to healthcare start-ups at present. "Fire sales of the small biotech firms held in Neil Woodford's funds depressed share prices and damaged sentiment across the board," Mr Penny said.We can be much more confident about a Nasdaq listing now than we were when we mentioned the possibility last year. When the firm announced in February the raising of £40m from seven new and existing investors (all but one of them American, unsurprisingly) it said: "The financing will strengthen the company's balance sheet as we continue to focus on accelerating revenue growth in 2021 and beyond, and marks a further important step towards our goal to dual-list on Nasdaq in 2021."But there are positive developments to report from the business's operations, too. Over the past year or so it has signed partnership agreements with four companies at the heart of what promises to be a whole new industry based on the "Crispr" gene editing tool, which won Nobel Prizes for chemistry for its inventors last year.The number of drugs being developed with the help of MaxCyte's "electroporation" machines has increased to more than 140, from about 100 at the time of our original tip, while the total in "milestones" the company could receive if all those drugs proved successful has risen from $800 (£578m) to "at least $950m".As we said before, not all of them will work but we can expect a success rate of perhaps a third. Meanwhile the company makes money by selling or leasing its machines, from the sale of consumables and, in a few years' time if all goes well, from royalties from successful treatments in which its technology was involved.Mr Penny acknowledged that "to some extent it requires the Nasdaq listing for the share price to remain high". But he added: "MaxCyte is a very special company. Maybe it's expensive for the London market but it's cheap for the US. The potential here is not just a rise of 10pc or 20pc. And at a market value of almost $1bn it is only just coming on some investors' radar." Questor says: holdTicker: MXCT
lomax99
29/4/2021
15:23
Updated research note "...The outlook is for sustained high top-line growth in FY 2021. The landscape is evolving fast, based on the exciting promise of the field of medicine, yet the industry is still in relative infancy and only a handful of first-generation cell therapies have achieved marketing approval reflecting the enormous potential to come. If its partners’ clinical trials run to plan, there are many new drugs likely to reach the market over the next 5-10 years that can provide royalty income streams, in addition to the aggregate potential US$950mln pre-commercial milestones. For this reason, MXCT is placed to continue to leverage its position, with a range of income streams providing, near term, and longer-term returns, and being an enabling technology embedded in these future clinical therapies, it has a unique and broad exposure to the field." hTTps://www.proactiveinvestors.co.uk/news/downloadResearchPdf/948094
pob69
29/4/2021
09:48
Yes, didn't struggle to pick up 2k around 8.40. No bargain though, had to pay 9.10.
assagai
29/4/2021
09:30
Can buy now - they must have found some stock.
someuwin
29/4/2021
09:23
Who won't?
assagai
29/4/2021
09:07
Won't let me buy any.
someuwin
28/4/2021
17:28
Familiar trading pattern. Sp seemingly remains flat of down all day and then jumps up at close. I suspect we’ll be revisiting previous highs again soon.
acuere
28/4/2021
10:30
The link works now... hTTps://www.trinitydelta.org/research-notes/catching-an-unbroken-wave/
al101uk
28/4/2021
08:49
George Ensor , Portfolio Manager at River & Mercantile commenting on large holding in MXCT. Remains bullish but had to sell some to rebalance overweight position to retain large position. hTTps://www.youtube.com/watch?v=wEtusObISCQ&t=2525s
pob69
27/4/2021
18:09
Sorry, don't have much more than I posted, they link to the site but it's been down all day... they do have this on their valuation: "Our £1bn (1217p/share) valuation is realistic In February 2021, reflecting the increasing visibility in partnered programme progress, we updated our valuation to include an rNPV contribution from these potential cash flow. Despite employing conservative assumptions, our valuation is £1bn ($1.3bn) valuation (1217p/share)."
al101uk
27/4/2021
17:02
Do they value off EBITDA or cash generation? The extract only mentions the former.
trident5
27/4/2021
16:24
AS Trinity Delta don't seem to be able to get their site back up, here's the intro they sent in the email: "MaxCyte’s strong FY20 performance was flagged in February’s trading statement. Revenues were up 21% to $26.2m despite known COVID impacts. EBITDA grew by 121% to $2.9m, before CARMA expenses, driven primarily by lower COVID spend due to pandemic-related restrictions. Potential pre-commercialisation milestones increased from >$800m to >$950m, with 140+ partnered programmes and 100+ covered by clinical licences. This operational momentum is expected to flow into FY21, with sustained revenue growth and new deals. With end-December 2020 cash of $34.8m, plus the $55.3m (gross) raised in February 2021, MaxCyte is well funded to invest in its technologies and processes; particularly scale-up in anticipation of product manufacture. Our £1bn ($1.3bn) valuation (1217p/share) reflects MaxCyte’s strategic importance and the potential value from the partner pipeline." Looks like they are re-affirming their "conservative valuation" of £12.17 per share after results.
al101uk
27/4/2021
14:24
there must be a subliminal read across to Seeing Machines in the last post....
waggle
27/4/2021
14:18
Site currently unavailable?
assagai
27/4/2021
13:34
Trinity Delta have posted an update on Maxcyte: hTTps://www.trinitydelta.org/research-notes/catching-an-unbroken-wave/ Site down right now though.
al101uk
27/4/2021
10:48
It certainly is quiet (though I note my previous post has traction on twitter. Feel free pepersoons to name me pob69 and thanks for spreading the word!) .... How about this in addition to CTX001 for sickle cell disease Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia hTTp://www.crisprtx.com/about-us/press-releases-and-presentations/vertex-and-crispr-therapeutics-announce-priority-medicines-prime-designation-granted-by-the-european-medicines-agency-to-ctx001-for-transfusion-dependent-beta-thalassemia
pob69
27/4/2021
10:11
Interesting, no ref to this or crisper/vertex progression. Maybe adds weight to "quiet period" argument.
assagai
27/4/2021
08:25
£600,000 contract win Supply of a VLX electroporation system including consumables, maintenance and repairs to the Centre for Process Innovation in Redcar. hTTps://bidstats.uk/tenders/2021/W16/749273501
pob69
23/4/2021
06:50
Good morning gsbmba99, Thank you for sharing your research ! Looks there is a high probability that we are in the "quiet period" with regards to a NASDAQ listing IMHO.
multibagger
22/4/2021
22:52
Https://www.investor.gov/introduction-investing/investing-basics/glossary/quiet-period If they have filed their registration statement with the SEC then they are in a quiet period and it will run until the registration statement becomes effective. I'm pretty sure there's a carve out for results and factual statements so their interpretation is probably on the conservative side. No problem with that. No point in getting sued or having registration statement postponed if the pipeline is described as "electric" when it is in fact merely "shockingly good". Extract from above link is below. "The federal securities laws do not define the term “quiet period.” However, that term is used to refer to the period of time surrounding the filing of a registration statement during which an issuer of securities must ensure that its offering-related communications comply with the federal securities laws. This period lasts, at a minimum, from the time an issuer files a registration statement with the SEC to the time that SEC staff declare the registration statement “effective.” During that period, issuers and other participants in the registered offering must be careful that any “offer” of the registered securities is made in accordance with the federal securities laws. The failure to comply with applicable restrictions on making “offers” is referred to as “gun-jumping.” Because the SEC and courts have broadly construed the term “offer” to include communications that might generate public interest in an issuer or its securities, the scope of communications that are potentially subject to restriction is quite broad."
gsbmba99
22/4/2021
21:33
Perhaps something to do with the Nasdaq listing. I recollect quite strict rules on what can and can't be said prior to an event. Prob easiest/safest just to stay schtum. (?)
rambutan2
Chat Pages: 30  29  28  27  26  25  24  23  22  21  20  19  Older
ADVFN Advertorial
Your Recent History
LSE
MXCT
Maxcyte
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210614 10:06:53